Tags: Drug.

Abarelix (trade name Plenaxis) is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.It was originally marketed by Praecis Pharmaceuticals as Plenaxis and is now marketed by Speciality European Pharma in Germany after receiving a marketing authorisation in 2005.

Abarelix.svg
ATC prefix
L02
ATC suffix
BX01
CAS number
183552-38-7
ChEBI
337298
DrugBank
DB00106
FDA UNII code
W486SJ5824
IUPAC name
acetyl-D-β-naphthylalanyl- D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L- N-methyl- tyrosyl-D-asparagyl-L-leucyl-L-N(e )-isopropyl-lysyl-L-prolyl-D-alanyl-amide
PubChem
16131215

Loading...

This page contains content from the copyrighted Wikipedia article "Abarelix"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.